drugset / Trial / NCT01527240

Neuroprotection Impact of Cyclosporin A in Cerebral Infarction

NCT01527240

Phase 2 Completed 126 enrolled Hospices Civils de Lyon
RandomizedParallel-groupDouble-blindTreatment

Summary

The main objective of this study is to determine whether a single injection of CsA after intravenous thrombolysis can significantly decreased the volume of cerebral infarction at day 30 ± 15 assessed with Flair MRI. Secondary objectives are to determine whether a single injection of CsA after intravenous thrombolysis is safe and effective regarding to death and disability.

Timeline

Start
2009-10
Primary completion
2009-10
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 2 mg/kg Intravenous

Indications